Skip to main content
Premium Trial:

Request an Annual Quote

RXi Awarded $600K NIH Grant to Develop RNAi Rx

Premium

RXi Pharmaceuticals this week announced that it has received a two-year grant worth up to $600,000 from the National Institutes of Health to fund the preclinical development of RNAi therapeutics and related delivery technologies.

The company said it will receive approximately $300,000 a year under the grant.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.